Podiatrists in Mason, OH Accepting Medicare
5 Podiatrists found. Showing 1 - 5
 Dr. Michael R Kiehl, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 5300 Socialville Foster Rd Ste 160, Mason, OH 45040 Phone: 513-844-8585 Fax: 513-844-8769 |
 Dr. Julia Sinclair Butts, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 5300 Socialville Foster Rd, Suite 160, Mason, OH 45040 Phone: 513-844-8585 Fax: 513-844-8769 |
Mr. Steven J Mccarthy, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5300 Socialville Foster Rd Ste 160, Mason, OH 45040 Phone: 513-844-8585 Fax: 513-844-8769 |
Gary Glynn, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6010 S Mason Montgomery Rd, Mason, OH 45040 Phone: 513-246-7000 Fax: 513-204-6355 |
Dr. Jeffrey S Schussler, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 7567 Central Parke Blvd Ste D, Mason, OH 45040 Phone: 513-535-3338 |
News Archive
Millennium presents three studies in relapsed multiple myeloma at IMW meeting
Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.
Simple method to purify cashew allergens could help scientists better understand allergic reactions
It's well known that peanuts can cause severe reactions in people who are allergic, but research suggests that the risk of developing a life-threatening reaction could be higher for those allergic to cashews. Now scientists have come up with a fast and simple method to purify the three main cashew allergens to help better grasp how they work and their effects on people.
China's progress in developing COVID-19 vaccines could surprise the world, GlobalData says
China is among the leading countries that are aggressively involved in developing vaccines for COVID-19, with one vaccine each from Sinopharm Group and Sinovac Biotech entering Phase 3 clinical development.
First glioblastoma patient treated with genetically modified poliovirus at UH
University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma, a deadly Grade IV cancer of the brain.
› Verified 9 days ago
Physical Therapists
Speech-Language Pathologists
Chiropractors
Occupational Therapists
Optometrists
Podiatrists
Audiologists